ArticleDiscover oncology2025
Development of a clinical prediction model for sensitivity to combination therapy of Bcl-2 inhibitors and hypomethylating agents in elderly/unfit patients with acute myeloid leukemia.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThis study aims to develop a clinical prediction model for sensitivity to Bcl-2 inhibitors combined with hypomethylating agents (HMAs) in elderly/unfit patients with acute myeloid leukemia (AML).
methodsClinical data, including French-American-British (FAB) classification, chromosomal karyotype, and second-generation sequencing results, were retrospectively collected from consecutive elderly/unfit patients with AML treated with Bcl-2 inhibitors in combination with HMAs between September 2019 and March 2024. Treatment efficacy was assessed in all patients. Logistic regression and Akaike information criterion were used to identify risk variables affecting efficacy. A nomogram was developed based on these variables to assess patient sensitivity to the treatment regimen. The performance of the nomogram was evaluated using a receiver operating characteristic (ROC) curve, calibration plot, and decision curve analysis (DCA).
resultsThis study included 209 patients with AML. The FAB classification, AML type, AML status, prior HMAs exposure, chromosomal karyotype, and mutations in ASXL1, FLT3, IDH, NPM1, and CEBPA were screened to develop the nomogram. The area under the ROC curve indicated a discriminatory power of 0.900 (95% CI, 0.860-0.941). The calibration curve suggested favorable concordance between the predicted and actual occurrence probabilities (P = 0.849). DCA revealed a net clinical benefit when the threshold probability ranged from 0 to 0.98. Internal validation, performed 500 times using the bootstrap method, demonstrated a satisfactory model performance in the validation set.
conclusionA prediction model was developed and validated to serve as a decision-making tool for physicians treating elderly/unfit patients with AML prior to initiating therapy with Bcl-2 inhibitors combined with HMAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.